This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Altria Group has been evolving with the changing industry dynamics. Given the rising health consciousness and stern government regulations to discourage smoking, this tobacco behemoth has been moving beyond traditional cigarettes and expanding in the smokeless category. We note that revenues from the oral product category have been steadily rising on the back of growing popularity for reduced risk products. In this respect, Altria is gaining from the sale of IQOS in United States, through its licensing deal with Phillip Morris. Further, Altria’s investment in Cronos Group highlights its focus on exploring the cannabis market.
Is WisdomTree U.S. Dividend exFinancials ETF (DTN) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for DTN
Altria (MO) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Altria (MO) closed at $48.13 in the latest trading session, marking a -1.17% move from the prior day.
Philip Morris' (PM) IQOS, Beyond Nicotine Growth Plans On-Track
by Zacks Equity Research
Philip Morris (PM) benefits from the growing market for IQOS devices globally. It is also focused on the expansion of Beyond Nicotine products to support inhaled therapeutics.
Focus on Low-Risk Offerings Drives Altria (MO), Pricing Aids
by Zacks Equity Research
Altria (MO) strives to expand IQOS and on! amid consumers' rising preference on low-risk tobacco alternatives. Moreover, strong pricing for tobacco products is driving revenues.
Altria (MO) Stock Moves -0.04%: What You Should Know
by Zacks Equity Research
In the latest trading session, Altria (MO) closed at $46.71, marking a -0.04% move from the previous day.
Zacks Industry Outlook Highlights: Philip Morris, Altria Group and Turning Point Brands
by Zacks Equity Research
Zacks Industry Outlook Highlights: Philip Morris, Altria Group and Turning Point Brands
3 Tobacco Stocks to Watch Out For on RRPs and Pricing Gains
by Vidya Nair
The Zacks Tobacco industry gains from reduced-risk products and solid pricing. Such upsides have been benefiting companies like Philip Morris (PM), Altria (MO) and Turning Point Brands (TPB). However, regulatory headwinds in cigarettes are a concern.
Altria (MO) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Altria (MO) closed at $46.50 in the latest trading session, marking a +1.4% move from the prior day.
Altria (MO) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Altria (MO) closed at $48.74 in the latest trading session, marking a +0.58% move from the prior day.
The Zacks Analyst Blog Highlights: United Parcel Service, ServiceNow, CVS Health, Booking Holdings and Altria Group
by Zacks Equity Research
The Zacks Analyst Blog Highlights: United Parcel Service, ServiceNow, CVS Health, Booking Holdings and Altria Group
Top Stock Reports for United Parcel Service, ServiceNow & CVS Health
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including United Parcel Service, Inc. (UPS), ServiceNow, Inc. (NOW), and CVS Health Corporation (CVS).
Altria (MO) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Altria (MO) closed at $48.03 in the latest trading session, marking a -0.23% move from the prior day.
Philip Morris (PM) Strives to Expand IQOS & Beyond Nicotine
by Zacks Equity Research
Philip Morris (PM) is gaining from growing consumer acceptance for IQOS devices. It is on track with the expansion of Beyond Nicotine products to support inhaled therapeutics.
Altria (MO) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Altria (MO) closed the most recent trading day at $49.23, moving +1.78% from the previous trading session.
Altria (MO) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Altria (MO) closed at $50.88 in the latest trading session, marking a +0.18% move from the prior day.
Altria (MO) Benefits From Low-Risk Products, High Pricing
by Zacks Equity Research
Altria (MO) is gaining from rising popularity of IQOS and on!. Strong pricing for tobacco products is also driving revenue growth.
Philip Morris (PM) Gains on IQOS, Beyond Nicotine Expansion
by Zacks Equity Research
Philip Morris (PM) is gaining from rising popularity of IQOS devices. The company is also progressing with the expansion of Beyond Nicotine products that cater to medical wellness.
Altria (MO) Hikes Dividend, Boosts Shareholders' Wealth
by Zacks Equity Research
Altria (MO) raises quarterly dividend by 4.7% to 90 cents per share. The company's new annualized dividend rate is $3.60 per share.
Philip Morris (PM) Fuels Smoke-Free Offerings With IQOS ILUMA
by Zacks Equity Research
Philip Morris International (PM) unveils the launch of IQOS ILUMA. These bladeless devices generate no smoke and combustion, and will strengthen the company's smoke-free portfolio.
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Top Research Reports for Costco, Altria & Edwards Lifesciences
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Costco Wholesale (COST), Altria Group, Inc. (MO), and Edwards Lifesciences (EW).
Company News for Jul 30, 2021
by Zacks Equity Research
Companies In The News Are: NOK, YUM, MA, MO.
Altria (MO) Q2 Earnings Beat Estimates, Revenues Up Y/Y
by Zacks Equity Research
Altria's (MO) second-quarter performance reflects gains from growth in revenues across all categories, backed by favorable pricing variance and shipment volumes.
Altria (MO) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Altria (MO) delivered earnings and revenue surprises of 5.13% and 4.71%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Altria (MO) Lined Up for Q2 Earnings: Key Things to Note
by Zacks Equity Research
Altria's (MO) second-quarter 2021 results are likely to reflect solid pricing power and strength in oral tobacco products.